Avestar Capital LLC Invests $215,000 in Kenvue Inc. (NYSE:KVUE)

Avestar Capital LLC acquired a new stake in Kenvue Inc. (NYSE:KVUE) in the fourth quarter, Holdings Channel.com reports. The fund acquired 10,064 shares of the company’s stock, valued at approximately $215,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Huntington National Bank increased its stake in Kenvue by 26.5% during the third quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after acquiring an additional 871 shares during the last quarter. ING Groep NV increased its position in shares of Kenvue by 23.6% during the 3rd quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock worth $82,727,000 after purchasing an additional 681,954 shares during the last quarter. Everence Capital Management Inc. raised its holdings in Kenvue by 122.1% in the 4th quarter. Everence Capital Management Inc. now owns 45,380 shares of the company’s stock valued at $969,000 after buying an additional 24,950 shares during the period. Saturna Capital Corp lifted its position in Kenvue by 29.9% in the third quarter. Saturna Capital Corp now owns 1,334,860 shares of the company’s stock valued at $30,875,000 after buying an additional 307,039 shares during the last quarter. Finally, Golden State Equity Partners boosted its stake in Kenvue by 716.1% during the fourth quarter. Golden State Equity Partners now owns 25,658 shares of the company’s stock worth $548,000 after buying an additional 22,514 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Kenvue Trading Up 2.3 %

Shares of NYSE:KVUE opened at $21.94 on Friday. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46. The company’s 50 day moving average is $21.32 and its two-hundred day moving average is $22.07. The company has a market cap of $42.07 billion, a PE ratio of 41.40, a P/E/G ratio of 2.16 and a beta of 1.45. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts predict that Kenvue Inc. will post 1.05 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a yield of 3.74%. The ex-dividend date is Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is 154.72%.

Wall Street Analysts Forecast Growth

KVUE has been the topic of a number of research analyst reports. Bank of America boosted their price target on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a research report on Monday, February 3rd. Canaccord Genuity Group lowered their price target on Kenvue from $27.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Barclays decreased their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a research note on Friday, January 17th. Finally, UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $23.00.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.